Last reviewed · How we verify
metastatic biliary tract cancer
Approved treatments
Clinical guidelines
- FDA label — 1L
IMFINZI in combination with gemcitabine and cisplatin as treatment. - FDA label — neoadjuvant/adjuvant
IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- metastatic biliary tract cancer patent landscape — cliff calendar, originator estates, attackable patents
- metastatic biliary tract cancer treatment landscape brief
- metastatic biliary tract cancer treatment updates RSS
Frequently asked questions about metastatic biliary tract cancer
What are the treatment guidelines for metastatic biliary tract cancer?
FDA label publishes guidelines for metastatic biliary tract cancer. 2 guideline references tracked.
Related
- Treatment landscape: metastatic biliary tract cancer patent cliff · metastatic biliary tract cancer CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing